Key result
Nano-crush stenting with ultra-thin sirolimus-eluting stents yields a ~6% 1-year target lesion failure rate.
Why the study?
Certain anatomical substrates of bifurcation lesions require two stents using dedicated techniques, but outcomes with ultra-thin sirolimus-eluting stents using the nano-crush technique were not well evaluated.
Observational (n=63)
No
Answers are grounded in this paper and cite their sources.
Nano-crush with ultra-thin SES appears feasible for dedicated bifurcation lesions; leaves open efficacy versus provisional stenting in randomized trials.
BACKGROUND: Provisional stenting is preferred for bifurcation lesion; however, certain anatomical substrate does require two stents as a part of dedicated stent technique. Here, the present study evaluated outcomes of ultra-thin (60 µm) Supra family sirolimus-eluting stent (SES) (Sahajanand Medical Technologies Limited, Surat, India) for dedicated bifurcation lesions using nano-crush technique at 12 months angiographic follow-up. METHODS: This was prospective, single-center observational study which enrolled patients with de novo bifurcation lesion and underwent angioplasty with Supra family SES using nano-crush technique at a tertiary care center in India, between March-2017 and February-2019. Primary endpoint at 12 months was target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV-MI), and clinically driven target lesion revascularization (CD-TLR). Secondary endpoints included patient-oriented composite endpoint (POCE), all-cause death, any revascularization, clinically driven target vessel revascularization, stent thrombosis, periprocedural and spontaneous MI, and device failure. RESULTS: The study enrolled total 63 patients with a mean age of 62.5±4.9 years and had male dominance (89%). Left main (LM) bifurcation and non-LM bifurcation were observed in 21 (33%) and 42 (67%) patients, respectively. Total 50 (80%) patients had Medina class- 1,1,1. At 12 months, TLF occurred in 4 (6%) patients which included one cardiac death (1.5%), two (3.0%) TV-MI, and one CD-TLR (1.5%). POCE was observed in 6 (9.6%) patients. Stent failure was seen in 2 (3.1%) patient and one patient (1.5%) developed late stent thrombosis. Twelve months angiographic follow-up indicated intact stent patency in all other patients. On multivariate analysis, LM bifurcation, renal dysfunction, LM bifurcation with renal dysfunction, ejection fraction (<35%) and calcified lesion were found as predictors of TLF. CONCLUSIONS: Dedicated stenting with ultra-thin Supra family SES for complex bifurcation lesion using nano-crush technique reported acceptable clinical outcomes among real-world patients and can be performed safely with ease without any procedural complications.
No takes yet. Share an insight, caveat, or question.
Prithwiraj Bhattacharjee (2022) conducted an observational in de novo bifurcation lesion (n=63). Ultra-thin (60 µm) Supra family sirolimus-eluting stent using nano-crush technique was evaluated on Target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TV-MI), and clinically driven target lesion revascularization (CD-TLR). Dedicated stenting with an ultra-thin Supra family sirolimus-eluting stent using the nano-crush technique resulted in a 6% rate of target lesion failure at 12 months.
Synapse has enriched 10 related papers. Consider them for comparative context: